[68GA]GA-PENTIXAFOR (CXCR4) PET/MR FOR INITIAL STAGING AND FOLLOW UP IN MULTIPLE MYELOMA: PROSPECTIVE COMPARISON WITH STANDARD OF CARE PET/CT AND EVALUATION OF THERAPY INFLUENCE

Registry ID

23-5828

Source registry

HEALTH_CANADA

Status

Ongoing

Study type

INTERVENTIONAL

Sponsor

UNIVERSITY HEALTH NETWORK

Start date

2025-01-14

Last update

2024-08-07

Conditions

• MULTIPLE MYELOMA

Related clinical trials

• A PHASE III, RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF CEVOSTAMAB IN COMBINATION WITH POMALIDOMIDE AND DEXAMETHASONE VERSUS STANDARD OF CARE IN PATIENTS WITH MULTIPLE MYELOMA WHO HAVE RECEIVED ONE TO THREE PRIOR LINES OF THERAPY
• PHASE I DOSE ESCALATION STUDY OF LIPOSOMAL CURCUMIN IN RELAPSED REFRACTORY MULTIPLE MYELOMA
• A MULTICENTER, RANDOMIZED, CONTROLLED, OPEN-LABEL, GROUP-SEQUENTIAL, PHASE 3 STUDY TO INVESTIGATE THE EFFICACY, SAFETY, AND TOLERABILITY OF INTRAVENOUS GAMMAGARD LIQUID (IMMUNE GLOBULIN INFUSION, 10%) FOR PRIMARY INFECTION PROPHYLAXIS COMPARED WITH SECONDARY INFECTION PROPHYLAXIS IN ADULT SUBJECTS WITH MULTIPLE MYELOMA RECEIVING B-CELL MATURATION ANTIGEN×CD3¿DIRECTED BISPECIFIC ANTIBODY THERAPY
• A PHASE 3, RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY TO COMPARE THE EFFICACY AND SAFETY OF BMS-986393, A GPRC5D-DIRECTED CAR-T CELL THERAPY, VERSUS STANDARD REGIMENS IN ADULT PARTICIPANTS WITH RELAPSED OR REFRACTORY AND LENALIDOMIDE-REFRACTORY MULTIPLE MYELOMA
• A RANDOMIZED, OPEN-LABEL, PHASE 3 TRIAL TO COMPARE THE EFFICACY AND SAFETY OF IDECABTAGENE VICLEUCEL WITH LENALIDOMIDE MAINTENANCE VERSUS LENALIDOMIDE MAINTENANCE THERAPY ALONE IN ADULT PARTICIPANTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA WHO HAVE SUBOPTIMAL RESPONSE AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION (KARMMA-9).
• LORATADINE FOR THE PREVENTION OF BONE PAIN CAUSED BY GRANULOCYTE COLONY STIMULATING FACTOR (G-CSF) DURING STEM CELL MOBILIZATION

View on source registry